Zeidan Amer M, Mahmoud Dalia, Kucmin-Bemelmans Izabela T, Alleman Cathelijne J M, Hensen Marja, Skikne Barry, Smith B Douglas
a Department of Internal Medicine , Yale University , New Haven , CT , USA.
b Celgene Corporation , Summit , NJ , USA.
Expert Rev Hematol. 2016 Jan;9(1):79-89. doi: 10.1586/17474086.2016.1112735. Epub 2015 Nov 14.
The economic burden associated with acute myeloid leukemia (AML) is poorly defined and understudied. The goal of this study is estimate the direct cost of illness for AML in the United States (US) and the United Kingdom (UK), by conducting a comprehensive literature review and calculating the average direct cost-of-illness per patient for the first 6 months of therapy. Patients were grouped by therapy: intensive chemotherapy alone; induction chemotherapy followed by allogeneic stem cell transplantation (alloSCT); low intensity therapy; and best supportive care. Data suggest that the pathways alloSCT, followed by intensive chemotherapy, are associated with the highest direct costs. Calculated direct costs suggest that they are higher in the US ($14,014 for BSC-only to $352,682 for alloSCT) than in the UK (£3708 [$5837] for BSC-only to £112,545 [$177,187]). AML appears to be associated with significant direct economic costs, but more studies are needed to fully assess the economic impact especially in relation to total and indirect costs.
与急性髓系白血病（AML）相关的经济负担目前定义不清且研究不足。本研究的目的是通过全面的文献综述，并计算治疗前6个月每位患者的平均直接疾病成本，来估算美国和英国AML的直接疾病成本。患者按治疗方式分组：单纯强化化疗；诱导化疗后进行异基因干细胞移植（alloSCT）；低强度治疗；以及最佳支持治疗。数据表明，alloSCT后再进行强化化疗的治疗路径与最高的直接成本相关。计算得出的直接成本表明，美国的直接成本（仅最佳支持治疗为14,014美元，alloSCT为352,682美元）高于英国（仅最佳支持治疗为3708英镑[5837美元]，alloSCT为112,545英镑[177,187美元]）。AML似乎与巨大的直接经济成本相关，但需要更多研究来全面评估经济影响，尤其是在总费用和间接成本方面。
